Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simvastatin: present and future perspectives.

Jennifer G Robinson1

  • 1Lipid Research Clinic, University of Iowa, Department of Epidemiology, Iowa City, IA 52242, USA. jennifer-g-robinson@uiowa.edu

Expert Opinion on Pharmacotherapy
|August 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction.

Pharmacy (Basel, Switzerland)·2022
Same author

Association of Low-Density Lipoprotein Cholesterol Levels with More than 20-Year Risk of Cardiovascular and All-Cause Mortality in the General Population.

Journal of the American Heart Association·2022
Same author

Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning.

Journal of biomedical informatics·2022
Same author

Trans Fatty Acid Biomarkers and Incident Type 2 Diabetes: Pooled Analysis of 12 Prospective Cohort Studies in the Fatty Acids and Outcomes Research Consortium (FORCE).

Diabetes care·2022
Same author

Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.

JAMA network open·2022
Same author

Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012).

Journal of thrombosis and thrombolysis·2021
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Simvastatin effectively lowers LDL cholesterol by up to 50% and reduces cardiovascular disease risk by 35%. It is recommended for high-risk patients, including those with diabetes, and requires dose adjustments with certain medications or severe kidney issues.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Simvastatin is a lipophilic statin metabolized by CYP450 3A4.
  • It has a short half-life.
  • Simvastatin is a widely prescribed lipid-lowering agent.

Purpose of the Study:

  • To summarize the efficacy and safety profile of simvastatin.
  • To outline dosing recommendations and contraindications.
  • To discuss current and developing formulations of simvastatin.

Main Methods:

  • Review of existing clinical data on simvastatin.
  • Analysis of pharmacokinetic and pharmacodynamic properties.
  • Evaluation of cardiovascular risk reduction and mortality data.

Main Results:

Related Experiment Videos

  • Simvastatin 5-80 mg doses reduce LDL cholesterol by 25-50%.
  • It reduces cardiovascular disease risk by 35% and mortality by up to 30% over 5 years.
  • A 40 mg starting dose is approved for high-risk patients, including those with diabetes.

Conclusions:

  • Simvastatin is an effective treatment for hyperlipidemia and cardiovascular risk reduction.
  • Dose adjustments are necessary for patients on CYP3A4 inhibitors, gemfibrozil, ciclosporin, amiodarone, or with severe renal insufficiency.
  • New formulations, including co-administration with ezetimibe, enhance therapeutic options.